MetP Pharma Receives US Patent for Drug Therapy of Demyelinating and Neuroinflammatory Diseases such as Multiple Sclerosis

MetP Pharma Receives US Patent for Drug Therapy of Demyelinating and Neuroinflammatory Diseases such as Multiple Sclerosis

Publication date: Dec 10, 2019

Research shows modulation of the Hedgehog and androgen signaling pathways to discontinue the vicious circle leading to inflammation in the central nervous system and chronic demyelination Treatment leads to functional recovery of axons associated with regeneration of myelin sheaths and reversal of pathological microglia activation in the chronic mouse model of experimental autoimmune encephalomyelitis New therapeutic strategy for demyelinating and neuroinflammatory diseases such as multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) MetP pursues additional patent applications in all major markets worldwide (PCT) EMMETTEN, Switzerland, December 09, 2019 / B3C newswire / — MetP(R) Pharma AG today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent entitled -Treatment of Demyelinating Diseases” (U. S. Appl.

Valid until 2039, the patent addresses a method to treat demyelinating diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) as well as other diseases in which neuroinflammation is a central pathological process.

The patent broadly covers demyelinating and inflammatory diseases of the central nervous system (CNS) such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Devic’s disease and Alzheimer’s disease; and demyelinating diseases of the peripheral nervous system such as Guillain-BarrcE9 syndrome, chronic inflammatory demyelinating polyneuropathy and Anti-MAG peripheral neuropathy.

Contact MetP Pharma AG Dr. Claudia Mattern CSO +41-41-618 30 30 Myelin Sheath; Amyotrophic Lateral Sclerosis 2, Juvenile; Amyotrophic Lateral Sclerosis; Encephalomyelitis, Autoimmune, Experimental; Multiple Sclerosis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Testosterone; Regenerative Medicine; Administration, Intranasal; Remyelination; Microglia; Signal Transduction; Axons; Central Nervous System; Inflammation Published by B3C newswire and shared through Newronic(R)

Concepts Keywords
ADHD Demyelinating disease
ALS Remyelination
Amyotrophic Lateral Sclerosis Experimental autoimmune encephalomyelitis
Androgen Multiple sclerosis
Autoimmune Intranasal delivery technology
Axons Regenerative Medicine
Blood Brain Barrier Drug delivery system
Brain Autoimmune diseases
Central Nervous System Neurology
Concussion Neurological disorders
Demyelinating Diseases Nervous system
Demyelination Organ systems
Drug Delivery Bypass
Hedgehog Signaling Pathway Amyotrophic Lateral Sclerosis
Immunomodulatory MS
Inflammation Demyelination diseases
Inflammatory Diseases Potential demyelinating diseases
Insomnia Inflammation
Internal Product Pharmaceutical manufacture services
Intranasal ALS diseases
Intranasal Administration Multiple Sclerosis
Microglia Diseases
Modulation Chronic demyelination
Multiple Sclerosis Intranasal delivery technology
Myelin
Nasal
Neurological
Newswire
Patent
Peripheral Nervous System
Peripheral Neuropathy
Pharmaceutical
Pharmaceutical Company
Progressive
Steroid Hormone
Switzerland
Syndrome
Synergism
Testosterone
United States
USPTO
Vicious Circle

Semantics

Type Source Name
disease MESH peripheral neuropathy
disease MESH polyneuropathy
disease MESH syndrome
pathway KEGG Hedgehog signaling pathway
drug DRUGBANK Testosterone
disease MESH Demyelinating Diseases
drug DRUGBANK Nonoxynol-9
disease MESH amyotrophic lateral sclerosis
disease MESH inflammation
disease MESH Multiple Sclerosis
disease MESH Polyradiculoneuropathy Chronic Inflammatory Demyelinating
disease MESH Encephalomyelitis Autoimmune Experimental
disease MESH Amyotrophic Lateral Sclerosis 2 Juvenile
disease MESH attention deficit hyperactivity disorder
disease MESH insomnia
disease MESH development
drug DRUGBANK Tropicamide

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *